Pharmacology · Antibacterial Agents

Chloramphenicol and Oxazolidinones

50S ribosomal inhibition — two classes, distinct mechanisms, contrasting toxicity profiles

Both chloramphenicol and linezolid inhibit 50S ribosomal function and both cause reversible bone marrow suppression through mitochondrial protein synthesis inhibition — but only chloramphenicol causes aplastic anemia, an idiosyncratic, dose-independent, unpredictable reaction with >50% mortality.
Chloramphenicol achieves CSF concentrations of 30–50% of plasma even without meningeal inflammation — the best CNS penetration of any protein synthesis inhibitor — making it an alternative for meningitis in severe beta-lactam allergy.
Linezolid is a reversible, nonselective MAO inhibitor — avoid with SSRIs, SNRIs, TCAs, meperidine, and tramadol; serotonin syndrome is a life-threatening risk.
Linezolid's ~100% oral bioavailability makes IV-to-oral conversion complete and seamless — oral linezolid achieves the same serum levels as IV, allowing outpatient completion of serious infections including MRSA osteomyelitis.
Linezolid is bacteriostatic against MRSA — do not use for MRSA bacteremia or endocarditis; use vancomycin or daptomycin instead.

Abbreviations: MRSA = methicillin-resistant Staphylococcus aureus · VRE = vancomycin-resistant Enterococcus · MAO = monoamine oxidase · SSRI = selective serotonin reuptake inhibitor · SNRI = serotonin-norepinephrine reuptake inhibitor · TCA = tricyclic antidepressant · CNS = central nervous system · CSF = cerebrospinal fluid · CBC = complete blood count · CYP = cytochrome P450

Chloramphenicol

Mechanism, Spectrum, and Pharmacokinetics

Chloramphenicol

Mechanism

Binds 23S rRNA at peptidyl transferase center on 50S subunit — blocks peptide bond formation
Bacteriostatic for most organisms; bactericidal vs. H. influenzae, N. meningitidis, S. pneumoniae

Spectrum

Gram-positive, gram-negative, anaerobes (B. fragilis), rickettsiae, Salmonella typhi
No reliable activity vs. MRSA or Pseudomonas aeruginosa

Pharmacokinetics

CSF: 30–50% of plasma without meningitis; rises toward plasma with inflammation — best CNS penetration among protein synthesis inhibitors
Hepatic glucuronidation → inactive glucuronide; immature in neonates → accumulation
Reduce dose in hepatic impairment; monitor serum levels

Toxicity and Clinical Role

Two Bone Marrow Toxicities

Reversible Suppression (Dose-Dependent)

All cell lines; plasma levels >25 mcg/mL
Fully reversible on stopping; prevented by monitoring

Aplastic Anemia (Idiosyncratic)

Unrelated to dose or plasma level — cannot be predicted or prevented by monitoring
~1 in 30,000 courses; onset weeks to months after exposure
Irreversible; mortality >50% without transplant

Drug Interactions and Modern Use

Inhibits CYP2C19 (major), CYP2C9, CYP3A4 — ↑ phenytoin and warfarin levels
Gray baby syndrome: neonatal glucuronidation immaturity → cardiovascular collapse
Systemic use: meningitis (severe beta-lactam allergy); brain abscess; MDR typhoid
Topical: bacterial conjunctivitis (systemic risk does not apply)

Oxazolidinones: Linezolid and Tedizolid

Mechanism, Spectrum, and Pharmacokinetics

Linezolid and Tedizolid

Mechanism — Unique Pre-Elongation Block

Block 70S initiation complex assembly — bind 23S rRNA on 50S, prevent 30S + 50S joining
No cross-resistance with macrolides, lincosamides, or chloramphenicol (different binding site)

Spectrum (Gram-Positive Only)

MRSA, vancomycin-resistant S. aureus, VRE, penicillin-resistant S. pneumoniae
Linezolid: also active vs. Mycobacterium tuberculosis (drug-resistant TB regimens)
No gram-negative activity

Linezolid vs. Tedizolid

Linezolid: ~100% oral bioavailability — IV = oral; no CYP metabolism; no renal dose adjustment; twice-daily dosing
Tedizolid: prodrug (plasma phosphatase activation); half-life ~12 hr → once-daily; 4–8× more potent; less myelosuppression than linezolid

Adverse Effects, Indications, and Resistance

Linezolid Toxicity Profile

Myelosuppression (Reversible)

Thrombocytopenia most common — appears after ~2 weeks
Fully reversible on stopping; monitor CBC weekly if course >2 weeks
Tedizolid: significantly less myelosuppression

Serotonin Syndrome (MAO Inhibition)

Linezolid = reversible nonselective MAO inhibitor — avoid with SSRIs, SNRIs, TCAs, meperidine, tramadol
Triad: mental status changes + autonomic instability + neuromuscular excitability

Neuropathy (Prolonged Courses)

Peripheral: stocking-glove paresthesias — may be irreversible
Optic: visual loss, color vision loss — may be permanent; monitor monthly if >4 weeks

Clinical Use and Resistance

MRSA pneumonia (ZEPHYR trial: superior to vancomycin); MRSA skin/soft tissue; VRE; MRSA osteomyelitis (oral step-down)
Not for MRSA bacteremia or endocarditis — bacteriostatic; use vancomycin or daptomycin
Resistance: 23S rRNA point mutations; cfr gene (rRNA methyltransferase, cross-resistance with chloramphenicol); tedizolid active vs. single-mutation isolates, not cfr-positive

Chloramphenicol vs. Linezolid — Key Distinctions

Feature	Chloramphenicol	Linezolid
50S binding site	Peptidyl transferase center — blocks elongation	Pre-elongation — blocks 70S initiation complex assembly
Spectrum	Broad: gram-positive, gram-negative, anaerobes, rickettsiae	Gram-positive only: MRSA, VRE, resistant pneumococci
CNS penetration	Excellent — 30–50% of plasma without inflammation	Good — adequate for CNS infections with susceptible organisms
Reversible marrow suppression	Yes — dose-dependent; levels >25 mcg/mL	Yes — mitochondrial; thrombocytopenia predominant
Aplastic anemia	Yes — idiosyncratic; ~1:30,000; irreversible; unpredictable	No
MAO inhibition	No	Yes — serotonin syndrome risk with serotonergic drugs
Oral bioavailability	~75–90% (oral chloramphenicol palmitate)	~100% — complete IV-to-oral interchangeability
CYP inhibition	Yes — CYP2C19, 2C9, 3A4; ↑ phenytoin and warfarin	No CYP metabolism — no CYP-based interactions

Key Distinction: Shared and Unique Toxicities

Both chloramphenicol and linezolid inhibit mitochondrial protein synthesis and both cause reversible bone marrow suppression — but the mechanisms differ: chloramphenicol's reversible suppression is dose-dependent and plasma-level related, while linezolid's thrombocytopenia reflects time-dependent mitochondrial accumulation. Chloramphenicol uniquely causes aplastic anemia — a dose-independent, idiosyncratic reaction that cannot be predicted by monitoring and carries >50% mortality without transplant. Linezolid does not cause aplastic anemia.

Linezolid uniquely inhibits MAO — creating serotonin syndrome risk that chloramphenicol does not share. Never combine linezolid with SSRIs, SNRIs, TCAs, meperidine, or tramadol. If a patient requires both, the serotonergic drug must be held for an appropriate washout period (typically 14 days for irreversible MAOIs, though linezolid's MAO inhibition is reversible — risks remain for the duration of the course).

Suggested References

Author / Source	Title	Publication
Katzung BG, ed.	Basic and Clinical Pharmacology, 15th ed. — Chapter 44: Tetracyclines, Macrolides, Clindamycin, Chloramphenicol, Streptogramins, and Oxazolidinones	McGraw-Hill, 2021
Brunton LL, Knollmann BC, eds.	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. — Chapter 51: Protein Synthesis Inhibitors and Miscellaneous Antibacterial Agents	McGraw-Hill, 2023
Falagas ME, Grammatikos AP, Michalopoulos A	Potential of old-generation antibiotics to address current need for new antibiotics	Expert Rev Anti Infect Ther. 2008;6(5):593–600
Schlunzen F, Zarivach R, Harms J, et al.	Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria	Nature. 2001;413(6858):814–821
Bhutta ZA	Current concepts in the diagnosis and treatment of typhoid fever	BMJ. 2006;333(7558):78–82
Turton JA, Havard AC, Robinson S, et al.	An assessment of chloramphenicol and thiamphenicol in the induction of aplastic anaemia in the BALB/c mouse	Food Chem Toxicol. 2000;38(10):925–938
Holt DE, Hurley R, Harvey D	A reappraisal of chloramphenicol metabolism: detection and quantification of metabolites in the sera of children	J Antimicrob Chemother. 1995;35(1):115–127
Yunis AA	Chloramphenicol toxicity: 25 years of research	Am J Med. 1989;87(3N):44N–48N
Swaney SM, Aoki H, Ganoza MC, Shinabarger DL	The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria	Antimicrob Agents Chemother. 1998;42(12):3251–3255
Ippolito JA, Kanyo ZF, Wang D, et al.	Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit	J Med Chem. 2008;51(12):3353–3356
Wunderink RG, Niederman MS, Kollef MH, et al.	Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study (ZEPHYR trial)	Clin Infect Dis. 2012;54(5):621–629
Flanagan S, Minassian SL, Morris D, et al.	Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment	Antimicrob Agents Chemother. 2014;58(11):6484–6491
Prokocimer P, De Anda C, Fang E, Mehra P, Das A	Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial	JAMA. 2013;309(6):559–569
Attassi K, Hershberger E, Alam R, Zervos MJ	Thrombocytopenia associated with linezolid therapy	Clin Infect Dis. 2002;34(5):695–698
Lawrence KR, Adra M, Gillman PK	Serotonin toxicity associated with the use of linezolid: a review of postmarketing data	Clin Infect Dis. 2006;42(11):1578–1583
Toh SM, Xiong L, Arias CA, et al.	Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid	Mol Microbiol. 2007;64(6):1506–1514
Mendes RE, Deshpande LM, Jones RN	Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms	Drug Resist Updat. 2014;17(1–2):1–12